There are approximately 140,000 new cases of cancer per annum in Europe in men less than 45 years old, with testis cancer, the commonest cancer in men of reproductive age making up about 10 % of this. Most of these men will be cured, thus their post treatment fertility is of significant importance. Men with newly diagnosed cancer frequently have abnormal spermatogenesis at the time of diagnosis, as indeed is often the case in men with systemic disease generally. This complicates analysis of the effect of treatment as that treatment will be acting on already abnormal spermatogenesis in many men. It has however been known for many years that men treated for cancer, particularly with alkylating agents are subfertile and alkylating agent based therapies for e.g. Hodgkin lymphoma have resulted in azoospermia in the majority of men treated. Damage to spermatogenesis is reflected in elevated serum FSH concentrations and low Inhibin B concentrations. Most men will have a normal serum testosterone unless they have received very high dose alkylating agent based therapy, but some will have elevated LH concentrations indicating compensated damage to the Leydig cells. It is possible that their ability to produce normal amounts of testosterone will decline in an accelerated form of normal ageing, thus long-term monitoring is required. Damaged spermatogenesis may also be reflected in damage to chromosomes and DNA. Such damage is also elevated in men prior to treatment but is commonly detected post chemotherapy, even many years later indicating damage to spermatogenic stem cells. It has also been demonstrated in survivors of cancer treated in childhood, reflecting spermatogonial turnover before puberty. This raises the issue of potential effects on subsequent progeny of the cancer survivor, although the epidemiological evidence is generally reassuring. DNA damage in survivors may however be associated with reproductive outcomes such as increased risk of miscarriage, by extrapolation from data from studies of infertile men, although there is no direct evidence for this in cancer survivors. Radiotherapy also causes significant damage to the testis. Differentiating spermatozoa are very sensitive but spermatogenesis stem cells are also sensitive to radiotherapy with Leydig cells much less sensitive. Recovery following treatment can be very prolonged, sometimes taking many years. Overall, these findings indicated the need for consideration of potential effects on fertility of men at the time of diagnosis, with referral for semen cryopreservation when appropriate.
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In addition to uncertainty over the risk of infertility associated with different oncologic treatment regimens, techniques available for fertility preservation in children and young adults are limited and their risk-to-benefit ratio remains unclear. Some treatments for childhood cancer can lead to infertility in later life but there is little clear evidence-based consensus on which patients are assessed as being at high, medium and low risk of subfertility in adulthood. It is time to consider fertility preservation in women as one of the foremost challenges of the next decade and to offer women facing the risk of induced or iatrogenic premature menopause the best chances of becoming mothers Patients are often unable to process the impact of a new cancer diagnosis on their fertility at the initial oncology consultation. For this reason, it is critical that the physicians who care for this young cancer population are sensitive to the unique issues inherent to this patient group. But when a patient with a fertility threat is interested in options for preservation, often no information is given and, at best, a discussion of the potential options for fertility preservation is held at the very end of the initial cancer diagnostic work-up. Therefore, a consultation with a fertility specialist is advisable taking into account that very often oncologists may not have the complete information affecting their ability to present a balanced approach to fertility preservation options. Among different approaches, embryo cryopreservation is the most established method for fertility preservation, and oocyte cryopreservation has gained efficacy and is now offered at many centers. Embryo cryopreservation has been proven to be safe and effective with reliable results in couples undergoing in vitro fertilization (IVF) treatment. Other options such as ovarian tissue cryopreservation are also available. Despite the fact that there have been less babies born using this method compared to embryo or oocytes cryopreservation in the last decade, frozen-thawed ovarian tissue reimplantation should no longer be considered an experimental procedure, and, in some cases, is the only suitable method for fertility preservation. Furthermore, in certain type of cancers, uterus or ovaries may be affected and discussion on the chance of sparing surgery is mandatory. Therapeutic conservative approach for endometrial cancer or borderline tumors of the ovary are being considered. Experiences of different medical teams will be discussed. References Anderson RA, Weddell A, Spoudeas HA, Douglas C, Shalet SM, Levitt G, Walace HB. Do doctors discuss fertility issues before they treat young patients with cancer? Hum Reprod, 2008; 23: 2246-51 . Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril, 2013; 99: 1496-502 . Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril, 2013; 99: 1476-84 . Donnez J, Dolmans MM, Pellicer A, Díaz-García C, Sánchez Serrano M, Schmidt KT. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril, 2013; 99: 1503-13 Endometrial cancer is the most common malignancy of the female genital tract and in the United States 47,100 new cases were diagnosed in 2012 with 8,000 deaths resulting from this disease. Classically the initial therapeutic approach to an early stage endometrial cancer has been a staging laparotomy with a total hysterectomy and bilateral salpingo-oophorectomy and lymphadenectomy depending on findings. However 10 % of patients with endometrial cancer are afflicted by the disease during the reproductive period of their lives. Considering that the average age at first maternity is progressively increasing nowadays 10 % of the first births occur in patients over 35 years of age. Nevertheless, recent data show that the mortality rate for uterine cancer has increased more rapidly than its incidence rate. For this reason we must clearly differentiate between endometrial cancer and uterine sarcoma and select the ideal candidates to be treated conservatively considering the existing association between infertility and endometrial cancer. A majority of cases of endometrial cancer in young patients are of early stage and low grade tumours, thus associated with an excellent outcome. We must select the criteria to be applied in the identification of the appropriate candidates for this kind of treatment and following the results of SEER analysis (Surveillance, Epidemiology and End results) we now know that the requisites are: a) Grade 1 well differentiated tumour b) Absence of lymph vascular space invasion (LVSI) c) No evidence of myometrial invasion on MRI d) No evidence of metastatic disease on CT scan e) No evidence of adnexal pathology on CT scan or pelvic ultrasound f) Strong and diffuse expression of progesterone receptors on immunohistochemistry staining of the endometrial biopsy. We also know the different risk factors (Obesity, PCOS, chronic excessive unopposed estrogen levels, diabetes, hypertension).
When the candidates are identified, we must counsel them regarding risks and benefits because we still have a lot of unanswered questions such as the need for conservative surgery preserving ovaries, use of Assisted Reproductive Techniques (in vitro maturation, oocyte or embryo cryopreservation), the different therapeutic strategies to offer to the patients, expected results and relapse rate and long-term safety. Despite a large number of pooled papers, the total number of patients treated with these protocols remains low. Of all women attempting to conceive, in the literature we have found a 47 % live birth rate and a remission rate of 81 % with a relapse rate of 28 %. A total of 18 % of patients failed up front hormonal therapy and required hysterectomy. It is now time to include well-selected patients suffering from stage 1 and low grade endometrial cancer and to propose them homogenous protocols of treatment and follow up.
Uterine transplantation

Mats Brännström
Department of Obstetrics & Gynecology, Sahlgrenska Academy, University of Gothenburg, Sweden
One of last frontiers to conquer in treatment of female infertility is absolute uterine infertility (AUFI). It is estimated that around 1:500 of women of reproductive age suffer from AUFI, with gestational surrogacy and biological adoption being the only means to acquire motherhood today. The patients with AUFI are those that lack a uterus from birth (MRKH-syndrome) or through hysterectomy (cervical cancer, myoma, peripartum emergency hysterectomy) in addition to those that have a non-functional uterus (Ashermans's syndrome, myoma, uterine malformation). Uterine transplantation (UTx) may become a treatment options for these women. Our research group initiated animal-based research on UTx in 1999 after the concept of UTx, was introduced to us by a young patient with cervical cancer that would undergo a radical hysterectomy. Three years later (2002), the first human attempt of UTx became public. A research paper described this human UTx case, where a 26-year-old hysterectomized woman received a uterus from a 46-year-old live donor. The transplantation took place in Saudi Arabia, but was not prepared by any research by the team. Although the surgeries of the donor and recipient were initially successful, the uterine graft had to be removed after 3 months because of prolapse with secondary necrosis. This first human UTx attempt stimulated further research in the area and several UTx-animal models such as the rat, mouse, pig and sheep have been used extensively during the last decade, with also non-human primate UTx studies being included during the last few years. In August 2011, the world's second human UTx attempt was performed in Turkey, when a young woman with the MRKH-syndrome received a uterus from a young braindead heart-beating donor. The transplantation team had no research record in UTx. The use of a deceased donor avoided the risky donor operation and facilitated recovery of a uterine graft with long vascular pedicles, which included the common iliac arteries and veins. The patient received only anti-thymocyte globulin during the first 7 days and has since then been on standard triple immunosuppression, with tacrolimus as calcineurin inhibitor. The uterus has now survived for almost 2 years. Pregnancies have been achieved at early ET attempts, but these have ended in early spontaneous abortions. Between September 2012 and April 2013 our team completed the surgeries of a series of totally nine human UTx, with live uterus donors (ClinicalTrials.gov NCT01844362). Most recipients were MRKH patients and a majority of the donors were mothers to the recipient. All patients had undergone IVF treatments before UTx and embryos had been cryopreserved. The surgical procedures had been prepared by our team for >5 years, with training mainly in the sheep, pig and baboon models. Altogether ten surgeons (four gyne-oncology surgeons, three gynecologists, three transplant surgeons) took part in the human UTx surgery in two adjacent ORs. The surgery of the recipients involved isolation of the uterus with long vascular pedicles of the uterine arteries and veins, all to their branchings from the internal iliacs. The most time-consuming part of the surgery was dissection of the thin-walled uterine veins that had to be freed from their close connections to the ureters. Moreover, several deep branches from these veins had to be ligated. After procurement from the donor the uterus was flushed with cold Custodiol and kept at cold ischemia until the recipient was fully prepared in an adjoining OR. Through a sub-umbilical midline incision, the external iliac artery and vein were mobilized bilaterally. The vaginal vault was separated from the bladder and ureters. The uterus was then brought into the pelvis of the recipient. Bilateral end-to-side anastomosis was accomplished between the uterine artery and one major uterine vein on each side, using continuous 7-0 sutures. After blood flow had been re-established, the vaginal rim of the grafted uterus was sutured to the vaginal vault by interrupted 2-0 sutures. The graft was fixed bilaterally to the round, cardinal and sacrouterine ligaments and an extensive leaf of bladder peritoneum of the graft was sutured on top of the bladder for extra structural support. The recipients received two ATG treatments iv and was then put on standard triple immunosuppression with tacrolimus, prednisolone and mycophenolate. The 6-month results of these 9 UTx procedures will be presented. Moreover, the techniques of donor and recipient surgery will be presented. In conclusion, 11 human UTx attempts have now been performed in the world. None of these has so far been successful in terms of birth of a healthy baby. We predict that this will happen in 2014.
Natural cycle IVF/M for clinical application
Ri-Cheng Chian
Professor, State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China Associate Professor, Department of Obstetrics and Gynecology, McGill University, Montreal, Canada Attempts to study human oocyte maturation in vitro (IVM) were first reported by Pincus and Saunders (1939) . It has been confirmed by Edwards (1965) that human follicular oocytes are able to mature in vitro when they are isolated from follicles and placed in appropriate culture medium. The human oocyte surrounded by cumulus cells has a higher maturation rate than those without these cells (Kennedy and Donahue, 1969) . The successful fertilization, development, and pregnancy with immature human oocytes matured in vitro were reported subsequently (Veek et al. 1983; Prins et al. 1987; Cha et al. 1991; Trounson et al. 1994; Barnes et al. 1995 Barnes et al. , 1996 . Initial IVM treatment was performed for women infertility with PCOS, and then IVM technology was expanded to treat the over responders and the poor responders for gonadotropin stimulation. It has been estimated that more than 2,000 babies born with IVM treatment in the worldwide, and the clinical pregnancy and implantation rates were approximately 30-35 % and 10-15 % per embryo transfer, respectively (Chian et al. 2004a) . It is a common believe that the recruit of the dominant follicle in the ovaries would suppress the development of other follicles and would induce other follicular and oocyte atresia. Recent studies in the animal model indicated that the maturational and developmental competence of immature oocytes derived from the small antral follicles is not adversely affected by the presence of a leading follicle or phase of folliculogenesis (Chian et al. 2002) . Furthermore, this notion has been confirmed in human and that the maturational and developmental competence of immature oocytes is not detrimentally affected by the presence of a dominant follicle during the follicular phase (Chian et al. 2004b ). It has been attempted using IVM technology to treat patients with normal menstrual cycle and intact ovaries. As protocols, the patients were administrated 10,000 IU human chorionic gonadotropin (HCG) 36 h before oocyte retrieval in natural cycle when the leading follicle reached to 12-14 mm in diameter. The results indicate that mature oocytes can be retrieved when the leading follicles reached 12-14 mm in diameter after HCG administration (Lim et al. 2007) . It is important to identify the mature oocytes at egg collection. Following transfer the resulted embryos, the clinical pregnancy and implantation rates are approximately 45 % and 25 % respectively. This new technology has to be defined as natural cycle IVF combined with IVM, namely Natural cycle IVF/M, in order to distinguish with traditional concept of IVM treatment. Recently it has been reported that natural cycle IVF/M together with IVM treatment can offer more than 50 % of total infertile women with acceptable pregnancy and implantations rates (Lim et al. 2009; Yang et al. 2012 The second half of the 2000s has brought a tremendous advance in assisted reproduction, consisting on the possibility to successfully cryopreserve the female gamete. After more than two decades of continuous efforts made to improve cryopreservation techniques, evolution and perfection of different vitrification strategies has allowed the achievement of efficient and reproducible protocols. The competence of this technology has been confirmed by the increasing body of literature showing that the vitrification of the female gamete is currently providing high outcomes under different clinical indications. Nowadays, it is possible to efficiently run ovum donation programs based on egg-banking, greatly alleviating the logistics of the whole donation process and increasing the safety due to the possibility of saving the quarantine period. Additionally, vitrification has also shown to be effective in autologous IVF cycles including different clinical indications as low responders, advanced maternal age, risk of ovarian hyper-stimulation syndrome, circumstantial absence of semen sample, etc. Evidence on the efficiency of this technology has encouraged both, clinicians and patients to consider oocyte vitrification as a viable option for fertility preservation (FP).
Owing to the increasing number of young women that fully recover from cancer due to improved and modern therapies, their future fertility has become a very relevant issue. The advent of vitrification as means of FP has opened a window of opportunity for many cancer patients to be a mother after having overcome the disease. Additionally, elective oocyte vitrification is being increasingly applied as an option to delay motherhood when modern life forces women to postpone the age to conceive. Despite the simplicity of this technique, there is a certain drawback associated to vitrification, especially in cancer patients, which is the need for controlled ovarian stimulation (COS) to obtain the oocytes, delaying the initiation of chemotherapy and the likely elevation of E 2 blood levels. The use of aromatase inhibitors in these sensitive cases has been very useful to avoid the raise in E 2 levels during COS. In our experience the mean E 2 after applying Letrozole stimulation was maintained low (381 pg/ml) although the risk of a weak response in breast cancer patients was 3 times higher than in the non-hormone-dependent patients. In a very recent publication we have summarized our 5 years-experience using oocyte vitrification for FP in oncological (N =475) and nooncological (N =560) patients. Comparable results were obtained in both groups of patients. A total of 30 patients have returned to use their oocytes. So far, six healthy babies have been born in our institution as a consequence of applying oocyte vitrification for FP. This technique offers realistic expectations to women to have a child with their own eggs after overcoming a malignant disease or due to other reasons. Continued collection of evidence is required, in order to clarify certain aspects that may remain unclear, as the number of oocytes required according to individual cases. Interdisciplinary communication will ensure the appropriate counsel in all cases where FP could be applied.
Is there a place for anti-leukemic in-vitro treatment of ovarian cortex prior to transplantation?
César Díaz-García Introduction: Retrasplantation of cryopreserved ovarian cortex from patients diagnosed of Leukemia implies a risk of reintroduction of malignant cells. Dexamethasone has proved its effectiveness to induce leukemic cell death in vitro. The aim of the present study was to evaluate the effect of Dexamethasone treatment on leukemic cell presence after retransplantation of cryopreserved ovarian tissue from patients diagnosed of leukemia. Methods: Cryopreserved ovarian tissue from patients diagnosed of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) was thawed and split in six fragments measuring 25 mm 2 . For each patient, three of the fragments were randomly allocated to incubation with M199 medium+ DXM (DXM group) and three to incubation with M199 alone (CONTROL group). After incubation, each ovarian fragment was transplanted to different SCID mice in an intra-peritoneal location. Six months after transplantation the animals were euthanized and systematic sampling was performed from the ovarian tissue, liver and any visible tumor for histologic (HE+ IHC) and molecular biology analysis.
Samples from patients having specific molecular markers were tested using such markers. All the samples from ALL patients were also tested for IgH monoclonality. Results: Thirty-six animals were transplanted and none of them developed any sign of clinical disease during the followup. Histologic analysis of the tissue samples revealed no sign of microscopic infiltration. Residual disease was detected by IgH monoclonality expression in three of the mice in the DXM group and three more animals were positive for IgH monoclonality in the CONTROL group. Conclusions: Although no clinical disease was diagnosed 6 months after transplantation in any of the transplanted animals, caution must be paid due to the fact that residual disease could be detected in both intervention groups. DXM incubation prior to retransplantation showed no differences as compared to the control group regarding detection of residual disease.
Risk of transplantation of malignant cells in fertility preservation
Marie-Madeleine Dolmans
Cliniques Universitaires St Luc, Gynecology Unit, Brussels, Belgium
Reversing treatment-related premature ovarian failure by means of autotransplantation of frozen-thawed ovarian tissue harvested before chemo-radiotherapy is becoming an increasingly realistic prospect for clinical application, with 30 live births already reported using this technique. Our objective is to offer young patients at risk of post-treatment premature ovarian failure safe fertility preservation options. One major concern raised by transplantation of ovarian cortical fragments in cancer patients is the potential risk that the cryopreserved ovarian tissue might harbor malignant cells that could induce disease recurrence after reimplantation, especially in case of blood-borne malignancies. Hematological malignancies and breast cancer are the most frequent indications for ovarian tissue cryopreservation. Both carry the risk of ovarian metastasis. We therefore decided to conduct a study to evaluate the presence of leukemic cells and breast cancer cells in cryopreserved human ovarian tissue from patients with chronic myeloid leukemia, acute lymphoblastic leukemia, and advanced breast cancer. In each case, histology, polymerase chain reaction for diseasespecific markers, and long-term xenografting were used to test the frozen-thawed ovarian tissue. Molecular analysis showed that malignant cells may be present in ovarian tissue from acute leukemia patients and give rise to tumor development in mice after xenografting (n =5/12, acute leukemia). For mice grafted with ovarian tissue from patients with advanced breast cancer, PCR and MGB2 gene sequencing were positive in ovarian tissue in five out of ten patients, but none of the xenografted mice developed tumor masses during the 6-month grafting period. Although several studies have tested and demonstrated the safety of ovarian tissue reimplantation in Hodgkin's lymphoma patients, in non-Hodgkin's disease, the risk is higher. Indeed, malignant cells were recently detected in ovarian tissue in 2 out of 32 patients (6 %). In conclusion, while the malignant potential of these cells after thawing and grafting is not yet known (at least for breast cancer and NHL), the current study demonstrates that conventional histology and IHC need to be associated with more sensitive screening methods, like PCR and sequencing, before ovarian tissue transplantation can be contemplated. It should be stressed, however, that no disease recurrence has so far been noted worldwide after ovarian tissue reimplantation.
Current methods of fertility preservation
Jacques Donnez
Director of SRI, Society for Research into Infertility, Brussels, Belgium Aggressive chemotherapy and/or radiotherapy and BMT can cure >90 % of girls and young women affected by diseases requiring such treatment. Nevertheless, the risk of impairing gonadal function is high, particularly when gonadotoxic drugs (especially alkylating agents) are used. Embryo and oocyte cryopreservation are the options of choice (and endorsed by the ASRM) if chemotherapy can be delayed, giving patients with cancer the hope of a successful pregnancy when they have overcome their disease. In prepubertal girls and patients who require immediate treatment, ovarian tissue cryopreservation is the only available method. In the future, cryopreservation of ovarian tissue might be combined with the removal of small antral follicles (by puncture), making it possible to freeze both ovarian tissue and isolated immature oocytes, including those present in the dissection medium. Indeed, they might be highly abundant in the medulla, especially in very young patients. In July 2013, the American Society of Clinical Oncology (ASCO) added some clarifications to the 2006 ASCO recommendations, with the goal of updating guidance for healthcare providers. Health-care providers (including gynaecologic oncologists, paediatric oncologists and haematologists) should address the possibility of infertility with patients requiring treatment with gonadotoxic drugs and/or irradiation as part of the informed consent procedure and advise them as to available methods of fertility preservation, referring them to appropriate reproductive specialists. In the ASCO recommendations, it is stressed that no patients should be excluded from discussion of fertility preservation options for any reason (such as age, prognosis or parity), even if financial or insurance barriers might be present. Optimizing techniques and minimizing the risks of fertility preservation strategies represent the challenges of the next decade. In the near future, indications for benign diseases (such as recurrent endometriosis) and social reasons will also become increasingly frequent, even if the most immediate concern is helping women affected by cancer.
Surgical Techniques in Tissue Transplantation for Fertility Preservation
Tommaso Falcone
Professor & Chair, Department of Obstetrics & Gynecology, Cleveland Clinic, Cleveland, OH, USA Several techniques have been proposed for autologous ovarian tissue transplantation that have been broadly divided into heterotopic and orthotopic. No pregnancies have been reported with heterotopic transplants that can be directly attributed to the transplant. Before transplantation is considered there are several parameters that must be considered in order to properly counsel the patient on the risks and benefits of the procedure. The outcome will be dependent on the age of the patient at the time of tissue harvesting and any treatment already received. The next consideration should be risk attributed to transplanting malignant cells within the transplanted tissue. The amount of tissue harvested is dependent on an assessment of the risk of ovarian failure from the treatment of the underlying malignancy. Pelvic irradiation and alkylating agents carry the highest risk. The amount of tissue transplanted is often dependent on how much tissue is available. The most typical place for transplantation is at the site of an in situ ovary. The scarred cortex is removed to access the medulla. The frozen thawed tissue is then sutured to that area with 8-0 delayed absorbable suture. The use of minimally invasive techniques such as robotics may aid in faster postoperative recovery. Another technique is to make an incision on the cortex and suturing the tissue over the incision. A third approach is to make a tunnel under the cortex and pass the tissue under it so it is held in place by the surrounding tissue. In this case the transplanted tissue is effectively beneath the cortex of the atrophic in situ ovary. If the ovaries are absent then a peritoneal window is created under the broad ligament near where the ovary was located and the fragments are placed. If the transplanted tissue fragments are large (10×5 mm) either technique can be used. If the tissue fragments are small (2 mm main limitation of the technique is tissue ischemia. Few techniques exist for decreasing ischemia which has a direct impact on the longevity of the graft.
Which young female patients with cancer may benefit from fertility preservation?
W.H. Wallace
University of Edinburgh, Royal Hospital for Sick Children, Edinburgh, UK With 80 % of young patients with cancer surviving 5 years from diagnosis and 70 % becoming long-term survivors the issue of fertility outcome has become an issue of great importance . Female fertility preservation provides significantly different challenges to that for the male (Wallace et al. 2005 ). Embryo freezing is now an accepted and wellestablished procedure in many centres, but is not available for children who do not have a partner. Cryopreservation using vitrification of mature oocytes has become increasingly successful, but requires the patient to go through a course of hormone stimulation and is therefore not appropriate for children and young girls. Ovarian tissue cryopreservation has the potential advantages of preservation of a large number of oocytes within primordial follicles, it does not require hormonal stimulation when time is short, and is appropriate for the pre-pubertal girl. Disadvantages include the need for an invasive procedure, and the uncertain risk of ovarian contamination in haematological and other malignancies. Ovarian tissue cryopreservation in adult women with later re-implantation has resulted in at least 20 live births worldwide. This invasive approach to fertility preservation remains unproven and experimental in children and adolescents. With the recently described model of non-growing follicle decline in healthy women it seems likely that cryopreservation of immature ovarian tissue will be rich in non-growing follicles (Wallace and Kelsey 2010 ). An important question is does AMH have a role to play in predicting which patients may benefit from fertility preservation ? Most published studies that report AMH in normal girls and women include only a relatively small age range, thus a 'datadriven' approach has been used (Kelsey et al. 2012 ). This involved extracting data using a semi-automated procedure, and combined it with other unpublished data. The resulting combined dataset (n =3,260; age range −0.3 years to 54 years) (Kelsey et al. 2011 ) forms a representative sample of AMH levels in the population of healthy female humans, and can therefore be used as a basis for a predictive model of serum AMH level with changing age and was used to generate and validate the model. This model, which will be presented, demonstrates that the interpretation of AMH concentrations in girls and young women is complex and is unlikely to be a useful indirect indicator of ovarian reserve.
We strongly recommend that all young patients with cancer have an assessment made of their fertility prognosis before they commence treatment . We have previously published guidelines for patient selection in young female patients with cancer and in this lecture I will report our practise in a single centre that has offered fertility preservation since 1996. The clinical records of all 407 female patients treated for cancer, leukaemia or brain tumours at the Edinburgh Children's Cancer Centre who were <18 years old at diagnosis between 1st January 1996 and 30th June 2012, were reviewed retrospectively to assess current ovarian function. Ovarian cryopreservation was offered to 9 % of our patients, and performed in 5 %. The procedure was safe and without complications. All but one of our patients who have thus far developed premature ovarian insufficiency were identified pre-treatment using our criteria. More research is required before ovarian tissue cryopreservation in young patients with cancer can be considered to be an established technique available to patients out with IRB approved studies.
Activation of dormant follicles
Kate Hardy
Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, London, UK Female mammals are born with a lifetime's supply of follicles, which diminishes throughout reproductive life. The majority of follicles in the ovary are at the primordial (resting) stage of development, consisting of a small immature oocyte enveloped by a layer of flattened granulosa cells. Throughout reproductive life a steady trickle of follicles start growing. Activation of follicle growth involves increasing proliferation of the flattened granulosa cells with an associated change in shape, which precedes or accompanies the onset of oocyte growth. However, the mechanisms regulating this process remain unclear. Understanding these mechanisms is important because deviations in the rate at which follicles initiate growth will have a significant bearing on fertility, the age of the menopause and disorders of ovulation in women. Studies of follicle development in mice lacking specific genes, and in ovaries or pieces of ovary cultured under different conditions in vitro, suggest that local growth factor signals play an important role in regulating early follicle development. Key growth factors, which can either be locally produced or secreted by different cell types within the follicle itself, include members of the Transforming Growth Factor (TGF)-beta superfamily, such as TGF-betas, Growth Differentiation Factors (GDFs) and Bone Morphogenetic Proteins (BMPs). However, while a number of growth factors have been implicated in early follicle development, the source and identity of the major factor or factors that signal a specific follicle to start growing remain uncertain. In addition, it is not clear which cell type receives the signal; the oocyte or the granulosa cells. Spatial and quantitative image analysis of histological sections of ovary has provided support for the idea that primordial follicles produce an, as yet unidentified, inhibitor that maintains the primordial follicles in a quiescent state (Da Silva-Buttkus, 2008 Proc Nat Acad Sci 106, 456). Current studies on the cell biology of granulosa cells as they change shape and start proliferating are now providing clues as to the nature of signals that activate follicle growth. Understanding the nature of the signal, for example whether it is stimulating granulosa cell proliferation or oocyte growth, will help us identify the trigger that shifts the follicle from a state of quiescence to its path towards ovulation.
Does oocyte integrity matter with cryopreservation of ovarian tissue?
S. Samuel Kim
Head, Reproductive Endocrinology and Infertility, University of Kansas Medical Center, Kansas City, KS, USA Cryopreservation of ovarian tissue is a valuable strategy for fertility preservation in females. Although slow freeze methods of ovarian tissue cryopreservation have been successful, with approximately 30 babies born after frozen-thawed ovarian tissue transplantation, a significant portion of follicles in ovarian tissue are lost due to cryoinjury. One of the most significant causes of cryoinjury is formation and growth of intracellular ice crystals. However, extra cellular ice formation can be equally detrimental in multicellular tissue. Ultra-structural damage of follicles, which disturbs cellular and molecular interaction, is unavoidable in the process of freezing and thawing. Irreversible damage to structures such as the oocyte cytoskeleton can be detrimental for follicle development. Thus, it is important to maintain both oocyte cellular (cytoskeleton, chromatin, and mitochondria) and genomic (mutation free, transcriptionally competent DNA) integrity for reproductive success. Indeed, post-cryopreservation disruption of oocyte cellular and genomic integrity may lead to abnormal oocyte maturation, fertilization, and embryo development. Vitrification can theoretically eliminate ice crystal formation and reduce cryoinjury. Over the past 5 years vitrification of mature oocytes and embryos has been very successful, resulting in improved reproductive outcomes. However, it is still unknown if vitrification of multicellular tissue can be as successful as that of individual cells. Our murine study demonstrated adverse effects on embryo development after fertilization of in vitro matured oocytes obtained from vitrified mouse ovaries. Furthermore, when DNA damage and repair was assessed after cryopreservation of ovarian tissue in a bovine model, repair mechanisms were not very efficient after vitrification, which resulted in elevated apoptosis rates (assessed by TUNEL staining and immunohistochemistry with cPARP). In addition, more intense condensation of nuclear chromatin was noted after vitrification. Chromatin condensation can be transient and reversible, but if not reversed it may become a serious insult eventually affecting embryo development and pregnancy outcomes. The effect of ovarian tissue cryopreservation on oocyte cellular and genomic integrity should be further investigated for the sake of healthy pregnancies. Although it has been clear for many years that chemotherapy treatment can lead to premature ovarian failure in premenopausal patients, what is much less certain is exactly how different drugs induce ovarian damage. In the past, it has often been assumed that damage is to oocytes contained within resting, primordial follicles. In contrast, it now appears that follicles at the primordial stage may be protected against directly-induced damage, their loss instead due to growth initiation following depletion of the growing follicle pool. We have now examined the effects of four chemotherapy drugs, each from a different class of chemotherapeutic agent and each often administered to girls or premenopausal women. Drugs examined were: a platinum-based alkylating-like agent, cisplatin; an anthracycline, doxorubicin; a taxane, docetaxel; and a topoisomerase type I inhibitor, irinotecan (examining the effect of its active metabolite SN38). We have used neonatal mouse ovarian tissue culture to examine their effects, allowing detailed examination of the direct ovarian response to these drugs, in highly controlled conditions. We have compared the concentration of drugs required to induce loss of around 50 % of follicles with patient serum concentrations for each drug, to obtain an indication of ovarian toxicity: the work shows that cisplatin, doxorubicin and docetaxel have similar levels of ovotoxicity, while that of irinotecan is substantially lower. In addition, all four drugs damage only growing follicles, with each drug leading to a drug-specific pattern of damage, acting through different cellular mechanisms. One consequence of this is that any treatments designed to protect the ovary from chemotherapy-induced damage may have to be tailored to the specific drug regimens used, as exemplified by results showing that imatinib mesylate can protect the ovary against damage by cisplatin, but not from doxorubicin-induced damage. This work was funded by MRC grant G1002118, with SM funded through a BBSRC studentship.
Mechanisms of chemotherapy-induced loss of ovarian follicles
Medical protection of gonadal/ovarian damage
D. Meirow, H. Roness
Center for Fertility Preservation, Sheba Medical Center, Tel Hashomer, Israel
Understanding the mechanisms underlying the impact of cytotoxic drugs on the ovary is fundamental to the development of improved techniques for fertility preservation. The ovary is composed of a heterogeneous population of cell types and follicle stages, each of which is affected differently by exposure to cytotoxic drugs. Of greatest importance is the impact of cytotoxic drugs on the dormant oocytes in the primordial follicles that comprise the ovarian follicle reserve and the patient's future fertility. It has recently been shown that some chemotherapy drugs trigger activation and growth of the dormant follicles, leading to burnout of the follicle stockpiles. Other studies have demonstrated evidence of vascular and stromal damage, which indirectly impact on the primordial follicles. Agents that can prevent the loss of follicles at the time of treatment would carry significant advantages over existing fertility preservation techniques in that they would be suitable for patients of all ages and life stages, and would not require invasive surgical procedures or subsequent use of assisted reproductive technologies. A number of possible candidates have been tested for their ability to prevent cytotoxic induced ovarian damage. The earliest proposed agents were based on animal studies which showed that suppression of the pituitary-gonadal axis with GnRH analogs during treatment conveyed ovarian protection. A number of large scale clinical studies have resulted in conflicting conclusions but there is some indication that treatment with GnRH can confer a measure of protection to the ovarian reserve.
Based on our understanding of the mechanisms behind chemotherapy-induced ovarian injury, recent studies have focused on manipulations of signaling pathways shown to play a role in cytotoxic-induced ovarian follicle loss. Agents such as sphingosine-1-phosphate and Iminatib, which act on the apoptotic pathways in the ovarian follicles, have demonstrated ovo-protective effects in animal models. Immunomodulator AS101 was shown to preserve the ovarian reserve during cytotoxic treatment by acting on the PTEN-PI3K pathway follicle activation pathway to reduce both dormant follicle activation as well as granulosa cell apoptosis.
New strategies in fertility preservation: a) Freeze/dry (lyophilization) of oocytes, stem cells and chromosomes and b) In vitro whole organ perfusion Storage of cryopreserved oocytes and stem cells in liquid nitrogen is very demanding in terms of maintenance, storage space, equipment and costs. Such demands are predicted to increase as more women are seeking to protect their future fertility or asking for cord blood banking. Among the options for fertility preservation, the ovarian cortical tissue preservation is gaining wider acceptance. However this strategy cannot be proposed to patients with leukemia (risk of ovarian colonization). To solve these issues we will discuss preliminary results on alternative strategies as lyophilization of oocytes, stem cells and chromosomes; and in vitro folliculogenesis by continuous perfusion of whole ovaries. We compared various cooling methods on the recovery and survival after freeze/dry of in vitro-matured MII bovine oocytes and mononuclear cells (MNC). Oocytes were cryopreserved with slow freezing (cooling rate 4°C/min.); or with rapid freezing (cooling rate 150°C/min.); or with vitrification using minimum drop size in IMT-4 (cooling rate >20,000°C/min.). The oocytes were lyophilized with VirTis for 24 h. The rehydration process took place at RT using double distilled water and TCM199 supplemented with trehalose. Both oocytes and MNC viability was assessed using the live/dead fluorescent stains Syto-13/PI for membrane integrity. The best recovery and survival after rehydration was obtained with vitrification as freezing method (88 % and 77 %, respectively). The rehydrated MNC were assessed with the colony forming unit (CFU) assay and compared to fresh samples (1). We also investigated whether meiotic chromosomes from in vitro matured MII ovine oocytes remain functional after complete lyophilization and rehydration. One group had the nucleus removed (minioocytes) while a second had the polar body removed (microocytes). After loading in empty zonas pellucida they were vitrified and submitted for lyophilization (Frezone Plus 6) for 24 h. Vials were vacuum-sealed and stored at RT until use. After re-hydration, the chromosomes, made visible after Hoechst 33342 staining and UV irradiation, were isolated from both groups and injected into previously enucleated fresh oocytes. The best results, survival, activation and cell division, were obtained with the lyophilization of chromosome from the polar body (microoocytes) with 56 % of reconstructed oocytes surviving injection and 33 % reaching the morula stage. Finally, to solve the issue of ovarian colonization from cancer cells (which preclude the safety of tissue cryopreservation and retransplant), we began experiments of in vitro whole ovine ovary perfusion to induce in vitro folliculogenesis. After 36 h of perfusion (hMG and hCG) follicular growth and oocyte retrieval was demonstrated. In summary: 1) Lyophilization is a potential groundbreaking innovation for bio-banking; 2) Vitrification of oocytes is an essential step for lyophilization; 3) Lyophilized chromosomes are capable to drive early embryonic development into enucleated, fresh oocytes; 4) Whole ovary perfusion can lead to in vitro folliculogenesis. The complete in vitro growth (IVG) and in vitro maturation (IVM) of oocytes from primordial follicles represents a valuable adjunct to strategies for the preservation and restoration of fertility in girls and women. An increased understanding of the genetic and epigenetic events and cellular checkpoints during oogenesis and folliculogenesis in vivo has supported the development of a number of different follicle culture strategies however, the nature, duration and success of these systems vary according to the species of interest and the stage of follicle development at the onset of culture. The culture of isolated primordial follicles is possible, but this approach is far from optimized in humans such that human primordial follicles tend to undergo abnormal activation and/or apoptosis when they are put into culture so they rarely survive longer than a few days. In contrast, the growth of primordial follicles in situ either in whole ovaries (mice) or in fragments of cortical tissue (ruminants, primates and humans) has consistently been shown to be a relatively effective way of inducing and maintaining long-term follicle and oocyte growth in vitro. To date the production of embryos and live offspring following the IVG and maturation of oocytes from primordial follicles has only been achieved in mice. Recent progress with in vitro folliculogenesis in large animals, primates and humans has been marked by the use of multiphase culture systems which support the in vitro production of preantral follicles from primordial and primary follicles grown in situ within ovarian cortex, followed by antral cavity formation and somatic cell differentiation in isolated, in vitroderived, preantral-staged follicles. In some, but by no means all of the systems used, preantral to antral development may be supported by encapsulation within biological scaffolds such as alginate gels. In contrast, the extensive IVG and IVM studies of sheep and human follicles conducted in the Leeds laboratories have shown that three-dimensional antral follicles can consistently be produced in vitro from both fresh and cryopreserved tissue using serum-free cultures without alginate gels or extracellular matrix. The in vitro-derived germ cells not only have a similar ultra-structure to equivalent cells grown in vivo but the oocytes produced from sheep preantral follicles over 35-40 days also have the capacity to undergo IVM to MII following exposure to the correct physiological triggers in vitro. The epigenetic health of in vitro-derived oocytes must be proven before these cells can be used therapeutically. In addition to their use for fertility restoration, IVG and IVM strategies have the added value as these methods can be used as a vehicles to directly test the ovotoxic impact of chemotherapy agents, drug combinations and novel ovarian protective therapies and to improve the efficacy of ovarian tissue and organ preservation protocols.
Early-stage cervical cancer and fertility-preserving surgery
In early-stage cervical cancer, when pelvic lymph nodes are negative, surgical treatment gives a very good survival rate ranging between 95 and 98 %. But loss of fertility is a serious consequence of the classical surgical approach: Radical hysterectomy with pelvic lymphadenectomy. As a consequence, fertility-preserving approaches have been proposed and accepted internationally. Cervical cancer is the 3rd most common cancer in women aged less than 40. According to the SEER data, up to 42 % of all cervical cancers are diagnosed in women prior to the age of 45. Today, the classical radical hysterectomy is no longer the "gold standard" for young women with small lesions. For FIGO stage IA1 without lympho-vascular space involvement, cold knife conisation is now recommended as a fertilitypreserving treatment, since the rate of parametrium and pelvic lymph node involvement is negligible.
In patients with FIGO stages Ia2 and small IB1 disease (2 cm and less), four (4) fertility-preserving treatments have been proposed in the last decade: 1)Radical vaginal or abdominal trachelectomy with pelvic lymphadenectomy, 2)Neo-adjuvant chemotherapy followed by pelvic lymphadenectomy and radical trachelectomy, 3)Neo-adjuvant chemotherapy followed by pelvic lymphadenectomy and cervical conisation, 4)Pelvic lymphadenectomy with simple vaginal trachelectomy (without parametrectomy). Even more conservative surgery in carefully selected patients is studied world-wide: Large conisation or simple trachelectomy with pelvic sentinel nodes only. Oncological results from the literature show that the recurrence rate is comparable to a radical hysterectomy with pelvic lympadenectomy: 4.5 % (Plante M. Gynecol Oncol, 111:S105, 2008) Oncologic outcomes after vaginal radical trachelectomy Obstetrical results from the literature confirm that pregnancies are possible after conservative treatments, with a higher rate of prematurity (Sonoda Y et al. Gynecol Oncol, 108:214, 2008) Pregnancy outcomes after radical vaginal trachelectomy
We can conclude that the fertility-preserving surgical techniques fulfill the requirements of radical treatment for invasive cervical cancer. The complication rate is low, the cumulative multicenter oncologic and reproductive outcome are very encouraging. It is evident though that pregnancy is at high risk. Spontaneous recovery of fertility and ovarian function
K. T. Schmidt
The Fertility Clinic, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
Young women treated for a malignancy are at risk of loss of ovarian function and thus fertility. This risk is dependent on the age of the patient, the types of drugs used, the cumulative dose, and the ovarian reserve of the patient. Studies have shown that the pre-treatment AMH level is a good marker of risk of loss of ovarian function with the less the risk the higher the AMH. Regardless of type of drug used it is common that women stop menstruating during the course of treatment, but amennorhea during treatment is not synonymous with permanent ovarian damage. Studies have shown that ovarian function can indeed return for up to 6 months after treatment, and that this will enable a lot of women to conceive after a successful cancer treatment.
We have conducted a questionnaire study designed to assess the ovarian function and fertility in young women above 18 years of age more than 2 years after end of treatment. All women had taken part in our ovarian tissue cryopreservation programme and had had an ovary removed for cryopreservation. Only 22 % of the women participating experienced premature ovarian insufficiency after treatment, and most of these had suffered from leukaemia. Forty percent of the women had actively tried to become pregnant after treatment and of these 72 % succeeded. The majority of the pregnancies occurred spontaneously within the first 3 months of trying. The women with the best fertility prognosis after cancer were women suffering from breast cancer, in which group 85 % had a spontaneous menstrual cycle after treatment. Although fertility preservation is important and indeed relevant for a lot of female cancer patients, it is important to know that not all will lose their ovarian function and that spontaneous recovery is possible enabling a lot of cancer survivors to get the children they want and to maintain their cycles. In women with only one ovary due to cryopreservation of the other, it seems that the remaining ovary, if not completely depleted of follicles by chemotherapy, will ensure a normal menstrual cycle and enable the woman to become pregnant.
Cryopreservation of human ovarian tissue: slow freezing or vitrification
Cryopreservation of human ovarian tissue is an important method of fertility preservation (FP), particularly for prepubertal girls, but also for many other young women facing early ovarian failure. When compared to vitrification of oocytes, much larger numbers of eggs can be stored within the ovarian cortical tissue. No ovarian hyperstimulation is needed, and the procedure can be carried out immediately. The resent pregnancy results from re-transplanted ovarian tissue are convincing.
In the beginning, slow freezing of ovarian tissue was used (Hovatta et al. 1996 Human Reproduction, Newton et al. 1996 Human Reproduction), and modifications (choice of the cryoprotectant) of this technique are still the most widely used methods. Most of the published pregnancies, also the one in our unit, have resulted from slowly frozen tissue, but there are already congress reports from achieving pregnancies and births from vitrified tissue. There are many different variants in these two procedures, and direct general comparison between them is difficult. We have made a direct comparison using ovarian cortical tissue from the same donors in parallel (Keros et al. 2009 Human Reproduction) . We also developed a clinical grade vitrification method in which the procedure meets all the requirements of the European tissue directive. It is a closed system without direct contact of the tissue with liquid nitrogen, and with no constituents of animal origin (Sheikhi et al. 2012 Human reproduction), and recently a simplified procedure with only one permeating cryoprotectant, ethylene glycol (EG) (Sheikhi et al. 2013 Fertility and Sterility) . We have studied the normality and viability of the thawed/warmed tissue in culture, but vitrified tissue has not yet been transplanted to women in our unit, being a new method. The electron microscopic structure, the best demonstrator of tissue viability, has been the main end point. Oocytes have been well maintained in both slow freezing in which Propanediol and sucrose were used as cryoprotectants, but the ovarian stroma, that is also important for the survival and development of the tissue after transplantation, was better preserved after our vitrification, using either a combination of three cryoprotectants; dimethyl sulphoxide (DMSO) 1,2-propanediol (PrOH) and EG supplemented with 10 mg/ml HSA. But the tissue survived equally well with only EG. Our vitrification is a fast procedure requiring good quality laboratory work. The published vitrfication procedures differ largely from each other, making the comparisons difficult.
Mechanisms controlling resting ovarian follicle recruitment from post-operative follow-up of ovarian transplants
Sherman Silber
Infertility Center of St. Louis, St. Luke's Hospital, St. Louis, Missouri, USA Materials and Methods: 14 women underwent thin ovarian tissue transplantation obtaining post-op follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and anti-Mullerian hormone (AMH) levels over a prolonged period of years. Aside from pregnancy rate and live birth rates already reported, our goal was to study the mechanisms of resting follicle recruitment.
Results: The return of ovarian function was robust and predictable for all parameters. Ovulation, menstruation, and Day 3 FSH always returned by 4.5 months. Once the FSH returned to normal, the AMH then began to spike to high levels, almost twice the AMH level of the ovary donor. The AMH level in the recipient then came down over the rest of the first year to much lower levels, one third that of the donor, whose AMH remained constant. The grafts last for many years despite a relatively low but constant AMH.
Conclusions:
The time for resting follicles to reach the menstrual cycle and ovulate is consistently 4.5 months. The recruitment of resting follicles in both adult and fetus is controlled by pressure. The fetal female sex cords (once meiosis is initiated by retinoic acid) must invade the tough stroma of the tunica albuginea, to prevent a massive sudden release of eggs, and must arrest in prophase. Likewise, when a thin ovary transplant begins to function, there is a massive release of eggs from the resting phase.
Development of fully grown oocytes from human immature follicles in a multi-step culture system Evelyn E. Telfer
Institute of Cell Biology and Centre for Integrative Physiology, The University of Edinburgh, Edinburgh, UK
The ability to develop human oocytes from the earliest follicular stages through to maturation and fertilisation in vitro could revolutionise fertility preservation practice. This has been achieved in mouse where in vitro grown (IVG) oocytes from primordial follicles have resulted in the production of live offspring. However, developing IVG systems to support complete development of human oocytes has been more difficult because of differences in scale of timing and size. The aim of our work is to determine whether complete oocyte development can be achieved from human ovarian tissue grown in a multi-step culture system. We have developed a dynamic 3 step culture system that supports the activation of primordial follicles (step1) growth of multilaminar follicles (step 2) and oocyte growth out-with the large follicular environment (step 3). Using this system a population of oocytes capable of reaching Metaphase II can be obtained. A large proportion of oocytes, whilst fully grown, do not reach Metaphase II. This presentation will focus on the challenge that lies ahead to improve quantity and quality of in vitro grown human oocytes and will discuss the testing and safety checks that will be required before this technology could ever be applied in a clinical setting. Finally, the prospect of using this system to support the differentiation of stem cells to oocytes will be considered.
Fertility preservation in male patients
Herman Tournaye
Centre for Reproductive Medicine, University Hospital of the Brussels Free University, Brussels, Belgium
Loss of testicular stem cells is mainly caused by both chemoand radiotherapy although loss can also occur because of specific genetic disorders, e.g.; 47,XXY Klinefelter's syndrome. Fertility preservation strategies may be proposed to patients who subject to testicular stem cell loss. In men undergoing sterilizing treatments, sperm cryobanking is considered as an efficient preventive strategy. Given the introduction of ICSI, oncologists should be encouraged to refer patients for cryobanking. Yet, adult cancer patients, referred for semen banking may be found azoospermic at the time of cancer diagnosis. If after extended preparation no spermatozoa are observed, a surgical sperm recovery procedure can be proposed. In patients with testicular cancer, testicular tissue from the removed testis has to be explored for mature spermatozoa. Even in patients with lymphoma (Hodgkin's and nonHodgkin's) again, spermatozoa can be observed in about 50 % of wet preparations of testicular biopsies. In adolescents, ejaculated sperm can be obtained, either by masturbation, either by penile vibrostimulation or electroejaculation. Whenever these techniques cannot be applied or failed, surgical sperm recovery and banking of testicular tissue may be an acceptable strategy. Since spermatogenesis starts only at puberty, the only spermatogenic cells that are present in the seminiferous tubules before the onset of puberty are the spermatogonia. Therefore fertility preservation in prepubertal boys lies within the preservation of their spermatogonial stem cells. While this approach should be considred as experimental, three options for preservation are currently under research: the spermatogonial stem cell transplantation, the grafting of testicular tissue pieces and the in vitro proliferation and/or maturation of spermatogonia. Each technique has of course its (dis)advantages, but each one of them might eventually find its way to the clinic. Preservation in 47, XXY Klinefelter patients is even more experimental because stem cells may be sex chromosomal disomic and the niche cells may be compromised by sclerosis and atrophy of the seminiferous tubules. Data from the literature indicate that existing semen-depots are infrequently used, this because of recovery of fertility potential with paternity, because of death, because good sperm quality was regained or because the patient did not want children. Patients should thus receive updated information about potential benefits and risks before embarking for cryobanking, either of spermatozoa or testicular stem cells.
Use of frozen/thawed ovarian tissue for hormone replacement
C. Yding Andersen
Laboratory of Reproductive Biology, University Hospital of Copenhagen, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark.
In contrast to freezing oocytes and embryos for fertility preservation, cryopreservation of ovarian tissue maintains the follicle as an intact unit. The follicle comprise the functional unit of the ovary, which upon transplantation has the capacity to restore the ovarian organ function in the sense that both endogenous hormone production and release of mature oocytes will take place. Thus, a woman having entered menopause who receive transplantation of frozen/thawed ovarian tissue will most likely experience menstrual cycles and regain fertility. Although the tissue may not work for extended periods of time, follicles will develop to the preovulatory stage, support oestradiol production and a functioning corpora luteum will produce progesterone during the luteal phase. A single preovulatory follicle per month is therefore in essence undertaking the organ function of the ovary, which is reflected by the fact that almost 90 % of the body's oestradiol during the preovulatory phase is produced by the dominant follicle. In the ageing ovary the fertility potential and the potential for producing sex hormones to some extent become dissociated. The hormone production is maintained relatively unchanged compared to younger years (i.e. the menstrual cycle levels of oestradiol and progesterone remain almost similar), whereas women in the forties experience reduced fertility probably reflecting aged oocytes. A similar picture is observed in women who entered menopause and have frozen/thawed ovarian tissue transplanted. Despite quite regular menstrual cycles that restore the normal hormonal balance, they express a relatively low ovarian reserve with low levels of AMH and often, depending on age, they experience an attenuated pregnancy potential. However, the functional lifespan of transplanted frozen/thawed ovarian tissue is surprisingly long, often it is beyond 5 years with just a fraction of one ovary transplanted and there are examples of women who maintain regular menstrual periods for almost 10 years. Normal women may therefore be able to expand the hormonal cycle and their reproductive life by transplanting cortex pieces that were frozen when she was young. Cortical tissue from one ovary is usually separated into around 25 pieces and frozen in individual ampoules. Since follicular recruitment in each of these 25 pieces of ovarian cortex appears to occur in a sequential fashion as in an intact ovary, an effective method for expanding the period of having endogenous hormone production may be at hand. Most importantly, ovarian tissue will start to work in most places of the body and can even be transplanted subcutaneously during local anaesthesia. This possibility may become interesting in the future, because half of girls born in western countries nowadays are estimated to have life expectancy of more than 100 years. Many women will therefore in the future be without menstrual cycles for around half of their lives. Some women may wish to prevent some of the sequelae that menopause induce and avoid the common risk of suffering from side-effects enforced by menopause, like osteoporosis and cardiovascular diseases, despite a prolonged period of menstrual cycles may slightly enhance the risk of breast cancer. Therefore, women may in the future, without compromising their natural fertility, be able to prolong the period in which they experience circulating levels of sex steroids by having small pieces of frozen/thawed ovarian tissue transplanted, one by one, to augment utilisation of the huge pool of ovarian follicles that normally undergo degeneration. Although many women will not want to continue having menstrual cycles beyond the natural menopause this new technique may be viewed as female anti-ageing.
